Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4147909 | 0.85 | ALDH1A1 (0.42) | KDM4EALDH1A1HPGDHTTNPSR1 | |
| SCHEMBL13808814 | 0.84 | DYRK1A (0.34) | — | |
| SCHEMBL8166508 | 0.82 | KDM4E (0.41) | KDM4EALDH1A1HPGDHTTNPSR1 | |
| SCHEMBL13808801 | 0.80 | CYP2C9 (0.41) | KDM4EALDH1A1HPGDALOX5TSHR | |
| SCHEMBL10069376 | 0.77 | CA12 (0.40) | KDM4EALDH1A1HPGDTDP1L3MBTL1 | |
| SCHEMBL5764199 | 0.77 | ALDH1A1 (0.46) | KDM4EALDH1A1HPGDHTTNPSR1 | |
| SCHEMBL27317222 | 0.77 | DRD2 (0.44) | KDM4EALDH1A1HPGDHTTNPSR1 | |
| SCHEMBL1067879 | 0.74 | KDM4E (0.43) | KDM4EALDH1A1HPGDHTTNPSR1 | |
| SCHEMBL22032149 | 0.74 | KDM4E (0.37) | KDM4EALDH1A1HPGDHTTNPSR1 | |
| SCHEMBL22084664 | 0.74 | KDM4E (0.37) | KDM4EALDH1A1HPGDHTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286201-A1 | POLYMORPH FORMS OF (S)-2-((4-BENZOFURANYL)CARBONYLAMINOMETHYL)-1-((4-(2-METHYL-5-(4-FLUOROPHENYL)THIAZOLYL)CARBONYL)PIPERIDINE | GLAXO GROUP LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| EP-2190842-A1 | POLYMORPH FORMS OF (S)-2-((4-BENZOFURANYL)CARBONYLAMINOMETHYL)-1-((4-(2-METHYL-5-(4-FLUOROPHENYL)THIAZOLYL)CARBONYL)PIPERIDINE | Glaxo Group Limited (GB) | 2010-06-02 | — | — | EP | disclosed |
| US-20090131688-A1 | METHOD FOR THE SYNTHESIS OF 4-BENZOFURAN-CARBOXYLIC ACID | ZACH SYSTEM (FR) | 2009-05-21 | — | — | US | disclosed |
| WO-2009034133-A1 | POLYMORPH FORMS OF (S)-2-((4-BENZOFURANYL)CARBONYLAMINOMETHYL)-1-((4-(2-METHYL-5-(4-FLUOROPHENYL)THIAZOLYL)CARBONYL)PIPERIDINE | GLAXO GROUP LIMITED (GB) | 2009-03-19 | — | — | WO | disclosed |
| US-6939866-B2 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2005-09-06 | — | — | US | disclosed |
| US-20040044015-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2004-03-04 | — | — | US | disclosed |
| EP-1326860-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2003-07-16 | — | — | EP | disclosed |
| WO-2003047584-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003047585-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING BENZOFURANYL SUBSTITUTED 3-CYANOQUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SOLID TUMOURS | ASTRAZENECA AB (SE) | 2003-06-12 | — | — | WO | disclosed |
| WO-2002030926-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044015-A1 | Quinazoline derivatives | NQO2, NRAS, TOP1 | KDM4E 3469/4885ALDH1A1 1295/4885HPGD 534/4885 |
| US-20090131688-A1 | METHOD FOR THE SYNTHESIS OF 4-BENZOFURAN-CARBOXYLIC ACID | COASY, HSD17B12, ALDH18A1 | KDM4E 1526/4885ALDH1A1 40/4885HPGD 633/4885 |
| US-20100286201-A1 | POLYMORPH FORMS OF (S)-2-((4-BENZOFURANYL)CARBONYLAMINOMETHYL)-1-((4-(2-METHYL-5-(4-FLUOROPHENYL)THIAZOLYL)CARBONYL)PIPERIDINE | HLA-DRB1, HLA-C, BRCA1 | KDM4E 3560/4885ALDH1A1 168/4885HPGD 1810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.